BioCardia to present CardiAMP heart failure data

BioCardia, Inc. reported that echocardiography data from its CardiAMP Cell Therapy program for the treatment of heart failure has been accepted as a Late Breaking Clinical Trial oral presentation at the Technology and Heart Failure Therapeutics (THT) Meeting.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

BioCardia, Inc. reported that echocardiography data from its CardiAMP Cell Therapy program for the treatment of heart failure has been accepted as a Late Breaking Clinical Trial oral presentation at the Technology and Heart Failure Therapeutics (THT) Meeting. This conference is scheduled for March 2-4, 2026, in Boston, Massachusetts.

The company furnished a press release as an exhibit, which provides additional detail on the CardiAMP heart failure data to be discussed at the meeting. This disclosure is characterized as an informational event rather than a financial or transactional update.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCardia (BCDA) announce in its latest 8-K filing?

BioCardia announced that echocardiography data from its CardiAMP Cell Therapy for heart failure was accepted for a Late Breaking Clinical Trial oral presentation at the THT Meeting in March 2026, highlighting ongoing clinical progress for its heart failure program.

What is the CardiAMP Cell Therapy program mentioned by BioCardia (BCDA)?

The CardiAMP Cell Therapy program is BioCardia’s investigational treatment for heart failure. In this filing, the company notes that echocardiography data from the program will be presented as a Late Breaking Clinical Trial at the THT Meeting, underscoring advancing clinical evaluation.

When and where will BioCardia present CardiAMP heart failure data?

BioCardia will present Late Breaking Clinical Trial echocardiography data from its CardiAMP Cell Therapy for heart failure at the Technology and Heart Failure Therapeutics (THT) Meeting, scheduled for March 2-4, 2026, in Boston, Massachusetts, according to the 8-K filing.

Does BioCardia’s 8-K include financial results or transaction details?

The 8-K focuses on an upcoming scientific presentation of CardiAMP heart failure data and does not describe new financial results or major transactions. It characterizes the disclosure under “Other Events” and provides a related press release as Exhibit 99.1.

What exhibit is attached to BioCardia (BCDA)’s February 3, 2026 8-K?

The filing attaches Exhibit 99.1, a BioCardia press release dated February 3, 2026, describing acceptance of CardiAMP Cell Therapy echocardiography data for Late Breaking Clinical Trial oral presentation at the THT Meeting, along with Exhibit 104 for the cover page interactive data file.

Is the CardiAMP data disclosure in the BioCardia 8-K considered 'filed' with the SEC?

No. BioCardia states that the information in Item 8.01, including Exhibit 99.1, is being furnished and not deemed “filed” under Section 18 of the Exchange Act, limiting potential liability and incorporation by reference unless specifically referenced elsewhere.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/03/2026 - 08:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2026

BIOCARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38999		23-2753988
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

320 Soquel Way
Sunnyvale, California 94085

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On February 3, 2026, BioCardia, Inc. issued a press release announcing that echocardiography data from the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4, 2026 in Boston Massachusetts.

A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.

The information in this Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		BioCardia, Inc. press release dated February 3, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.

/s/ Peter Altman, Ph.D.
Peter Altman, Ph.D.
President and Chief Executive Officer

Date: February 3, 2026

Source: View Original Filing on SEC EDGAR